Global wearable artificial kidney market is estimated to be valued at USD 9.11 Bn in 2024 and is expected to reach USD 22.46 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.8% from 2024 to 2031.
Report Coverage |
Report Details |
Base Year: |
2023 |
Market Size in 2024: |
US$ 9.11 Bn |
Historical Data for: |
2019 to 2023 |
Forecast Period: |
2024 To 2031 |
Forecast Period 2024 to 2031 CAGR: |
13.80% |
2031 Value Projection: |
US$ 22.46 Bn |
Figure. Global Wearable Artificial Kidney Market Share (%), By Region, 2024
![Global Wearable Artificial Kidney Market - IMG1](/sample/img/COH1490103-f1.webp)
Wearable artificial kidney is a compact machine that works similarly to a regular dialysis machine. It filters waste and excess fluid from the blood outside the body for patients whose kidneys have failed. The traditional dialysis process involves hooking patients to a large dialysis machine for several hours, multiple times a week. However, with wearable artificial kidneys, patients will have the freedom and flexibility to go about their daily lives without being physically tied to a dialysis center or machine. This portable technology could help improve quality of life for kidney failure patients.
Market Dynamics:
Global wearable artificial kidney market growth is driven by rising prevalence of end-stage renal disease, growing geriatric population, increasing demand for home hemodialysis treatment, and technological advancements in portable and wearable medical devices. However, high development costs associated with wearable artificial kidneys, long approval timelines from regulatory authorities, and lack of reimbursement policies in some countries hampers the market growth. Ongoing R&D activities to develop more efficient and miniaturized wearable dialysis systems are expected to create lucrative opportunities for market players over the forecast period.
Key Features of the Study:
- This report provides an in-depth analysis of the global wearable artificial kidney market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global wearable artificial kidney market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this includes B. Braun SE, AWAK Technologies, Blood Purification Technologies Inc., Nextkidney , Triomed AB, SB-KAWASUMI LABORATORIES, INC., Asahi Kasei Medical Co., Ltd., Nanodialysis BV, Semperit AG Holding, KidneyX.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global wearable artificial kidney market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global wearable artificial kidney market.
Detailed Segmentation-
- By Disease Stage:
- Acute Renal Disease
- End-stage Renal Disease
- By Dialysis Type:
- Hemodialysis
- Peritoneal dialysis
- By End User:
- Hospitals
- Ambulatory Surgical Centers
- Dialysis Centers
- Others
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Braun SE
- AWAK Technologies
- Blood Purification Technologies Inc.
- Nextkidney
- Triomed AB
- SB-KAWASUMI LABORATORIES, INC.
- Asahi Kasei Medical Co., Ltd.
- Nanodialysis BV
- Semperit AG Holding
- KidneyX